Travere Therapeutics Q1 2024 Adj EPS $(1.51) Misses $(0.99) Estimate, Sales $41.374M Miss $42.847M Estimate
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics (NASDAQ:TVTX) reported Q1 2024 adjusted EPS of $(1.51), missing estimates by 52.53% and marking a 64.13% decrease from last year. Sales were $41.374M, missing estimates by 3.44% but showing a 33.95% increase from the previous year.
May 06, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Travere Therapeutics reported a significant miss in Q1 2024 earnings and sales, with adjusted EPS down 64.13% YOY and sales missing estimates but up 33.95% YOY.
The significant miss in both earnings and sales compared to analyst estimates, coupled with a substantial year-over-year decrease in EPS, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100